Liuzzo J P, Ambrose J A, Diggs P
Department of Medicine, Division of Cardiology, Saint Vincent Catholic Medical Centers, New York, NY and New York Medical College, Valhalla, New York, NY, USA.
Aliment Pharmacol Ther. 2005 Jul 15;22(2):95-100. doi: 10.1111/j.1365-2036.2005.02511.x.
Patients with coronary artery disease presenting to an emergency department with chest pain are likely to undergo hospitalization in an attempt to elucidate its aetiology.
To examine whether coronary artery disease patients receiving proton-pump inhibitor therapy are associated with fewer chest pain events and evaluations.
A veteran patient population with documented coronary artery disease was identified, and chest pain episodes, emergency department visits and hospitalizations for chest pain were followed over 2 years. Patient outcomes between proton-pump inhibitor use and non-use of proton-pump inhibitor therapy were compared.
In 415 male patients, 23% utilized a proton-pump inhibitor and 77% did not. Proton-pump inhibitor therapy was associated with fewer chest pain episodes (12% vs. 26%, P = 0.002), emergency department visits, (12% vs. 24%, P = 0.044) and hospitalizations (13% vs. 24%, P = 0.086). The incidence of adverse events was decreased in the proton-pump inhibitor group: 70% fewer chest pain episodes (P = 0.002, RR = 3.3), 55% fewer emergency department visits (P = 0.049, RR = 2.2) and 53% fewer hospitalizations (P = 0.064, RR = 2.1). By multivariate analysis, proton-pump inhibitor therapy independently predicted a reduced prevalence of patients experiencing chest pain, emergency department visits, and hospitalizations [OR = 0.09 (0.04-0.21); 0.15 (0.06-0.40); 0.14 (0.05-0.40); all P < 0.001].
Proton-pump inhibitor therapy for veteran coronary artery disease patients is associated with fewer chest pain episodes, emergency department visits and hospitalizations for chest pain.
因胸痛到急诊科就诊的冠心病患者可能会住院，以试图明确其病因。
研究接受质子泵抑制剂治疗的冠心病患者是否胸痛事件和评估较少。
确定一组有冠心病记录的退伍军人患者群体，对其胸痛发作、急诊科就诊和因胸痛住院情况进行为期2年的跟踪。比较使用质子泵抑制剂和未使用质子泵抑制剂治疗的患者结局。
在415名男性患者中，23%使用质子泵抑制剂，77%未使用。质子泵抑制剂治疗与较少的胸痛发作（12%对26%，P = 0.002）、急诊科就诊（12%对24%，P = 0.044）和住院（13%对24%，P = 0.086）相关。质子泵抑制剂组不良事件发生率降低：胸痛发作减少70%（P = 0.002，RR = 3.3），急诊科就诊减少55%（P = 0.049，RR = 2.2），住院减少53%（P = 0.064，RR = 2.1）。通过多变量分析，质子泵抑制剂治疗独立预测胸痛、急诊科就诊和住院患者患病率降低[OR = 0.09（0.04 - 0.21）；0.15（0.06 - 0.40）；0.14（0.05 - 0.40）；所有P < 0.001]。
退伍军人冠心病患者使用质子泵抑制剂治疗与较少的胸痛发作、急诊科就诊和因胸痛住院相关。
